ClinicalTrials.gg
RecruitingNCT07071935EVENT ALSUpdated Jun 26, 2026

A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)

A Phase 2 interventional study of Non-invasive ventilation in Amyotrophic Lateral Sclerosis (ALS), Chronic Respiratory Failure and Neuromuscular Disease Patients, sponsored by University of Pennsylvania. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by University of Pennsylvania · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Planned enrollment
126th of 307
48 · median 33
Started
2026
with 32 others
Phase 2
89 of 440
8 open now
Primary completion
2029-05
later than 96 of 128 live
Registered
393rd of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 126th largest by planned enrollment of the 307 interventional ones that give a count, is one of 33 that started in 2026, is one of 89 in phase 2, reaches primary completion later than 96 of the 128 other live ones, and was the 393rd registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

92 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

Amyotrophic lateral sclerosis (ALS) is a disease that causes weakness of the muscles of the body. The disease can eventually lead to severe breathing problems, which is the most common cause of death from ALS. The treatment for breathing is non-invasive ventilation (NIV). It is a machine that helps a person breathe by pushing air in and out of their lungs through a mask worn over the face. Research has shown that NIV can improve the quality of life and survival of someone with ALS. Unfortunately, NIV is not equally beneficial for everyone. The investigators do not yet know the best time or method for starting NIV in ALS. Europe and Canada allow starting NIV much earlier in ALS than the United States. Current recommendations for starting NIV are based on the opinion of experts rather than large research studies. Medical insurance companies will not cover NIV until significant breathing weakness occurs. After NIV is started, there is no evidence-based guidance on the best way to adjust NIV to benefit patients as much as possible. Some patients have difficulty tolerating NIV, but it is not clear how to identify these individuals ahead of time.

The investigators have created a new prediction tool that can identify patients at high risk of breathing problems within the next 6 months. This may help the study team identify who is more likely to benefit from starting NIV early. The investigators have published a paper that shows that NIV helps people with ALS live longer. This paper also showed that patients get more benefit with use NIV for at least 4 hours per day. The investigators published another paper that measured a gas called carbon dioxide (CO2), which goes high if someone's breathing is weakened. This paper showed that patients with ALS may live longer when CO2 levels are lowered using NIV. The investigators also have data suggesting that certain characteristics may predict who is less likely to use NIV at least 4 hours per day.

In this study, the investigators will collect pilot data on starting early NIV in individuals with ALS who do not yet meet insurance criteria for covering NIV. The research team will first use their previously published prediction tool to identify patient risk. Then, subjects would be randomized to start early NIV or to usual care. The usual care group would eventually start NIV as would occur if the participants were not in the study.

The purpose of this study is to collect data to help the investigators plan a larger randomized clinical trial. This study has 4 objectives. First, the project aims to identify individuals who would benefit from earlier NIV. The research team will use the original prediction tool to identify risk of severe breathing problems within the next 6 months. Second, the project aims to show that it is feasible to start NIV early. Third, the project aims to gather data on the effect of randomization on symptoms, CO2 levels, and outcomes. Fourth, the project aims to identify traits that may make someone less likely to use NIV.

Read the detailed description

Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with high morbidity and universal mortality predominantly due to respiratory failure. Non-invasive ventilation (NIV) improves quality of life (QoL) and extends survival in ALS beyond any medication.1-3 However, the best timing for NIV initiation is based only on expert opinion.4,5 For example, clinicians in the United States initiate NIV much later than European or Canadian guidelines,4,6,7 as payers do not cover NIV until significant respiratory impairment occurs. While potentially beneficial, early NIV initiation could increase burden for patients due to mask intolerance, claustrophobia, and disturbed sleep, possibly negating any clinical benefit. Similarly, there are no surrogate endpoints to guide NIV settings and mask selection. Thus, clinicians employ generic approaches despite significant disease heterogeneity. Given the variable onset and progression of ALS, strategies for anticipating respiratory risk and personalizing NIV management are critical to maximize NIV benefit while reducing its burden.

The investigators' ultimate goal is to conduct Phase III multicenter clinical trials which investigate early NIV strategies to improve quality of life and survival in individuals with ALS. Before embarking on a large RCT of early NIV in ALS, it is necessary to collect pilot data on feasibility, effect sizes, and personal factors associated with NIV usage. The study team's prior work has developed a novel clinical prediction tool which can stratify ALS patients at presentation into high versus low risk of respiratory insufficiency within 6 months, capable of identifying an enriched subgroup suitable for an interventional study. The investigators have performed semi-structured interviews which suggest that ALS patients value being proactive about their respiratory care. The investigators have shown that improving transcutaneous carbon dioxide (CO2) levels is associated with improved survival in ALS, suggesting that transcutaneous CO2 could be a surrogate endpoint for guiding NIV management. The investigators also have found that factors at time of NIV initiation, such as ALSFRS-R speech and dyspnea scores, are significantly associated with NIV adherence.

Clinical Intervention: In this RCT of patients who have yet to meet insurance criteria for NIV coverage, the research team will randomize individuals to early NIV versus usual care, stratified by 6-month risk of respiratory insufficiency as determined by the investigators' previously published novel clinical prediction tool.

Objective(s): The objectives in this pilot study are to collect: 1) feasibility data on randomization to early NIV; 2) estimates of effect sizes of early NIV versus usual care on endpoints such as QoL, transcutaneous CO2, symptoms, and survival; and 3) identify factors present at time of NIV initiation which predispose to low hourly usage of NIV. The research team will analyze results across randomization groups, as well as assess the interaction between randomization and predicted risk of respiratory insufficiency.

Study Design: This study will be a 3-center phase II pilot randomized clinical trial of incident ALS patients diagnosed in the last 6 months.

Clinical Impact: The proposed study will help the investigators understand the feasibility and safety of starting early NIV in ALS. The study team will assess effect sizes on clinical endpoints, which will be critical for planning a future large RCT. Lastly, the study team will learn about patient characteristics that may predispose to lower NIV adherence. The investigators will examine results across randomization and the interaction with predicted risk of respiratory insufficiency. Leveraging the clinical prediction tool may help identify an enriched patient population suitable for future interventional studies.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)
  • Chronic Respiratory Failure
  • Neuromuscular Disease Patients
  • Neuromuscular Disease
  • Respiratory Insufficiency
  • Respiratory Insufficiency Requiring Mechanical Ventilation
  • Positive Pressure Ventilation
  • Non-invasive Ventilation
  • Non-invasive Ventilation Support
  • Non-invasive Ventilatory Support

Keywords

  • chronic respiratory failure
  • chronic neuromuscular respiratory failure
  • non-invasive ventilation
  • amyotrophic lateral sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with ALS using the Gold Coast Criteria within the last 6 months
  • Age ≥18 years
  • Willingness and ability to participate in study procedures
  • Provision of signed and dated form

Exclusion criteria

Exclusion Criteria:

  1. Current or prior or recommended/prescribed use of NIV including:

    i) bi-level positive pressure ventilation, such as a respiratory assist device or home ventilator ii) Current or prior use of continuous positive airway pressure, or "CPAP" therapy

  2. Forced vital capacity \<50% of predicted normal
  3. Maximal inspiratory pressure > -60 cmH2O (eg, -50 or -40 cmH2O would be excluded)
  4. Chronic use of supplemental oxygen at any part of the day
  5. Enrollment in hospice
  6. Current tracheostomy
  7. Prior history of sleep apnea where non-invasive ventilation was used or recommended
  8. Thoracic, abdominal, facial or ophthalmic surgery in the prior 6 weeks
  9. Coughing up blood
  10. Myocardial infarction in the previous 4 weeks
  11. Absolute to NIV, which includes lethargy, obtundation, facial fractures, active pneumothorax, and airway obstruction (such as a tumor)
  12. Presence of cognitive dysfunction that would impair ability to complete study procedures, as determined by neurology attending physician
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Early Non-invasive Ventilation

    Participants randomized to this arm will be assigned to start therapy with non-invasive ventilation.

    Device: Non-invasive ventilation

  • No intervention
    Usual care

    Participants randomized to this arm will receive usual care for amyotrophic lateral sclerosis.

Interventions

  • DeviceNon-invasive ventilation

    Non-invasive ventilation will be started earlier than usual respiratory care guidelines for ALS in the United States.

    Also known as: non-invasive positive pressure ventilation, bilevel positive airway pressure

06

What researchers measure

Primary outcomes

  1. Time to first use of non-invasive ventilation

    Number of days between randomization to first recorded overnight usage of non-invasive ventilation according to ventilation device data download.

    Time frame: From enrollment to end of follow-up at approximately 1 year

Secondary outcomes

  1. Quality of life questionnaire

    Quality of life will be measured by the ALS Specific Quality of Life questionnaire - short form (ALSSQOL-SF), a validated questionnaire to assess quality of life in terms applicable to a person with ALS. The questionnaire includes 20 questions scored on a scale of 0-10.

    Time frame: From enrollment to completion of follow-up at approximately 1 year

  2. Transcutaneous carbon dioxide

    Measured during the day in clinic using a transcutaneous carbon dioxide monitor. Units are in mmHg

    Time frame: From enrollment to end of follow-up at approximately 1 year

  3. Oxygen saturation using pulse oximetry

    Pulse oximeter used during the day during a clinic visit. Unites in % of saturated hemoglobin.

    Time frame: From enrollment to completion of follow-up at approximately 1 year

  4. Epworth Sleepiness Scale - Alternative (ESS-ALT) questionnaire

    The ESS-ALT includes 8 questions on likelihood of falling asleep during various activities and was designed for individuals with physical disabilities. Each question is rated on an ordinal integer scale of 0 (never) to 3 (high).

    Time frame: From enrollment to completion of follow-up at approximately 1 year.

  5. ALS Functional Rating Scale - Revised (ALSFRS-R) scores

    The ALSFRS-R is a 12-item standardized questionnaire to assess the motor function status of an individual with ALS. Each of the 12 components of the questionnaire are scored on a scale of 0 to 4, with 4 being normal/no symptoms at all and 0 being severely symptomatic with little or no function.

    Time frame: From enrollment to completion of follow-up at approximately 1 year.

  6. Karolinska Sleepiness Scale (KSS)

    The KSS questionnaire includes 1 question that is a 9-point ordinal integer scale asking the sleepiness level in the immediately preceding 10 minutes. The scale ranges from 1 (extremely alert) to 9 (very sleepy, great effort to keep awake, fighting sleep).

    Time frame: From enrollment to completion of follow-up at approximately 1 year.

  7. Global rate of change of breathing questionnaire

    The global rate of change score for breathing will obtain a participant's subjective sense of their breathing status. The global rate of change score for the breathing will ask patients how their breathing is today by rating it on a Likert scale from -7 (extremely impaired) to +7 (extremely strong).

    Time frame: From enrollment to completion of follow-up at approximately 1 year.

  8. Global rate of change of sleep quality

    The global rate of change score for sleep quality will obtain a participant's subjective sense of their sleep quality. The global rate of change score for the sleep quality will ask patients how their sleep quality is today by rating it on a Likert scale from -7 (extremely poor) to +7 (extremely good).

    Time frame: From enrollment to completion of follow-up at approximately 1 year.

  9. Tracheostomy-free survival time

    Number of days between enrollment and the end of follow up, study withdrawal, or death without interval placement of a tracheostomy.

    Time frame: Time in days between enrollment and either study withdrawal, death, placement of a tracheostomy, or completion of follow-up at approximately 1 year.

  10. Hospitalizations

    Number and time to hospitalizations during follow-up.

    Time frame: From enrollment to completion of follow-up at approximately 1 year.

  11. Average daily hourly usage of NIV

    This will be collected on subjects who are prescribed NIV within either study arm. Defined using telemonitoring portal data downloads (such as ResMed AirView for ResMed devices) which summarize average daily hourly usage over various specified time interval (e.g., the previous 30 days).

    Time frame: Between enrollment and completion of follow-up at approximately 1 year.

  12. Vital capacity

    Measured by performing a spirometry maneuver for vital capacity using a hand-held clinical-research grade spirometer in the sitting and upright position. Units are in liters.

    Time frame: From enrollment to completion of follow-up at approximately 1 year.

  13. Maximal inspiratory pressure

    Measured using a hand-held digital manometer with the patient in the sitting and upright position.

    Time frame: From enrollment to completion of follow-up at approximately 1 year.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Sarasate M, Gonzalez N, Cordoba-Izquierdo A, Prats E, Gonzalez-Moro JMR, Marti S, Lujan M, Calle M, Anton A, Povedano M, Farrero E. Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial. J Neuromuscul Dis. 2023;10(4):627-637. doi: 10.3233/JND-221658. PubMed 37212068 ↗
  • Gruis KL, Brown DL, Weatherwax KJ, Feldman EL, Chervin RD. Evaluation of sham non-invasive ventilation for randomized, controlled trials in ALS. Amyotroph Lateral Scler. 2006 Jun;7(2):96-9. doi: 10.1080/14660820600640604. PubMed 16753973 ↗
  • Ackrivo J, Hansen-Flaschen J, Wileyto EP, Schwab RJ, Elman L, Kawut SM. Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis. Eur Respir J. 2019 Apr 18;53(4):1802237. doi: 10.1183/13993003.02237-2018. Print 2019 Apr. PubMed 30728207 ↗
  • Ackrivo J, Hsu JY, Hansen-Flaschen J, Elman L, Kawut SM. Noninvasive Ventilation Use Is Associated with Better Survival in Amyotrophic Lateral Sclerosis. Ann Am Thorac Soc. 2021 Mar;18(3):486-494. doi: 10.1513/AnnalsATS.202002-169OC. PubMed 32946280 ↗

Individual participant data

Plan to share: Yes — Data dictionary and de-identified dataset

Supporting information: Study protocol, Informed consent form, Analytic code

Time frame: Upon study completion and for up to 3 years after study end date.

Access criteria: De-identified data available upon completion of a data sharing agreement

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2029, 35 months after the start.

Of 37 non-industry phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 41. This study's planned 35 months is close to that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2025
First posted
Jul 17, 2025
StartActual
Jun 11, 2026
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07071935
Collaborators
United States Department of Defense
Responsible party
Jason Ackrivo (Assistant Professor of Medicine and Neurology, University of Pennsylvania) — Principal investigator
First posted
Jul 17, 2025
Start date
Jun 11, 2026
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Jun 26, 2026

Study contacts

Jason T Ackrivo, MD, MSCE
Contact
jason.ackrivo@pennmedicine.upenn.edu
215-829-3053
Rebecca Lang Gallagher, MSEd
Contact
Rebecca.Lang@pennmedicine.upenn.edu
215-662-4088
Jason T Ackrivo, MD, MSCE
principal investigator · Perelman School of Medicine at the University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion